scholarly journals Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy

2021 ◽  
Vol 4 (1) ◽  
pp. 77-83
Author(s):  
Bando H ◽  
Kato Y ◽  
Kato Y ◽  
Matsuzaki S ◽  
Waka S ◽  
...  
Keyword(s):  
Renal Stone ◽  
Synergistic Effects ◽  
Glucose Variability ◽  
Diabetic Control ◽  
Daily Injection ◽  
Left Adrenal Gland ◽  
Multiple Daily Injection ◽  
Medical Histories ◽  
Diabetic Treatment

The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.

scholarly journals Urinary C-Peptide Excretion for Diabetic Treatment in Low Carbohydrate Diet (LCD)

2018 ◽  
pp. 13-18 ◽  
Author(s):  
Hiroshi Bando ◽  
Koji Ebe ◽  
Tetsuo Muneta ◽  
Masahiro Bando ◽  
Yoshikazu Yonei
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Glucose Variability ◽  
Carbohydrate Diet ◽  
C Peptide ◽  
Low Carbohydrate Diet ◽  
Low Carbohydrate ◽  
Diabetic Treatment ◽  
Average Glucose

Background: Arguments have continued about Low Carbohydrate Diet (LCD) and Calorie Restriction (CR). Authors have reported clinical research of LCD and Morbus (M) value. Subjects and Methods: Subjects enrolled are 84 patients with Type 2 diabetes mellitus (T2DM), 60.9 ± 10.9 years. The protocol were as follows: 1) CR diet on day 1, 2 with 60% carbohydrates, and LCD on day 3-14 with 12% carbohydrates, 2) Daily profile of blood glucose 7 times a day on day 2 (CR) and day 4 (LCD), 3) urinary C-Peptide radioimmunoassay (u-CPR) excretion, 4) M value calculation, 5) investigation of these data with correlation. Results: Subjects were classified into 4 groups according to M value, which were .4–21, 23–66, 29–192, 200–728, respectively. HbA1c value was 6.2, 8.0, 7.8, 9.2 %, respectively. Blood glucose in median from day 2 to day 4 were 123 to 107 mg/dL, 164 to 130 mg/dL, 193 to 156 mg/dL, 277 to 201 mg/dL, respectively. M value in median from day 2 to 4 was 6.3 to 9, 41 to 7, 108 to 16, 367 to 88, respectively. u-CPR was 88 to 58, 53 to 35, 65 to 52, 74 to 64, respectively. There were significant correlations among among glucose, M value and u-CPR. Discussion and Conclusion: Average glucose, M value and u-CPR decreased remarkably on day 4. As average glucose and M value were higher, decrease degree were larger. These results suggested that carbohydrate in meal would influence glucose variability in T2DM. Our data would become basic data for pathophysiological analysis of glucose variability research in the future.

scholarly journals Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis

Pharmacy ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 215
Author(s):  
Trisha Zeidan ◽  
Carla Nikkel ◽  
Beth Dziengelewski ◽  
Stephanie Wu ◽  
Aleda M. H. Chen
Keyword(s):  
Type 2 Diabetes ◽  
Daily Injection ◽  
Total Daily Dose ◽  
Diabetes Clinic ◽  
Multiple Daily Injection ◽  
Daily Dose ◽  
Study Completion ◽  
Glycemic Targets ◽  
Basal Bolus

Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D); however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (−1.5 ± 1.79%; p < 0.001). Patients prescribed insulin at baseline (n = 122) used significantly less insulin TDD (−8 u/day; p = 0.006). The percentage of patients meeting the target of A1C < 8% increased from 14% at baseline to 48% at study completion (p = 0.008). Patients prescribed a basal-bolus regimen prior to V-Go achieved an A1C reduction of 1.5 ± 2.0% (p < 0.0001) and experienced the greatest reduction in TDD (−24 u/day; p < 0.0001). Thus, patients switching to V-Go from a variety of therapies at baseline experienced reductions in A1C while using less insulin, with a reduction in clinically relevant hypoglycemia, indicating the potential benefit of V-Go in optimizing and simplifying T2D care.

scholarly journals Videocapillaroscopy, Insulin-Induced Skin Lipohypertrophy, and Bruising: A Preliminary Approach

2021 ◽  
pp. 1-4
Author(s):  
Teresa Della Corte ◽  
◽  
Gentile S ◽  
Guarino G ◽  
Cuomo G ◽  
...  
Keyword(s):  
Metabolic Control ◽  
Daily Injection ◽  
Skin Changes ◽  
Multiple Daily Injection ◽  
Poor Metabolic Control ◽  
Type 2 Dm ◽  
Injection Regimen

Background: Lipohypertrophy (LH) is a frequent cutaneous complication in people with insulin-treated type-2 DM (IT-T2DM). Its pathogenesis is not fully known, however. Retinal and kidney microangiopathy (MIA) is also frequent in such patients, especially in case of poor metabolic control. Aim: To assess whether specific nailfold video-capillaroscopy (NVC) patterns could be identified in MIA-affected IT-T2DM patients, thus eventually helping explain LH pathogenesis. Methods: 50 IT-T2DM patients with LH and 50 without LH undergoing NVC were enrolled. All followed a multiple daily injection regimen and had established retinal and renal microangiopathic complications. Results: While confirming expected MIA-related skin changes in both groups, our data failed to detect any specific NVC pattern in LH-affected patients yet showed the most severe NVC changes to be significantly associated with HbA1c values over 9%. Conclusion: Severe NVC-assessed MIA lesions reflect longstanding poor metabolic control in IT-T2DM rather than contributing to LH pathogenesis.

Clinical Outcomes of Patients with Type 2 Diabetes Treated with Multiple Daily Injection (MDI) of Insulin—A Retrospective Cohort Analysis

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2273-PUB
Author(s):  
THOMAS LUDDEN ◽  
ANASTASIA ERMAKOVA ◽  
YAN XIONG ◽  
RAY SIERADZAN ◽  
NAOMI C. SACKS ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Outcomes ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Daily Injection ◽  
Multiple Daily Injection ◽  
Retrospective Cohort Analysis

947-P: Glucose Variability: Insulin Pump vs. Multiple Daily Injection in Type 1 Diabetes Evaluated by Continuous Glucose Monitoring

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 947-P
Author(s):  
ADRIAN E. PROIETTI ◽  
ANDREA V. DAGHERO ◽  
MARIA LUJAN SCAPUZZI ◽  
MARIA L. IGLESIAS ◽  
JUAN PATRICIO NOGUEIRA
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Insulin Pump ◽  
Glucose Monitoring ◽  
Glucose Variability ◽  
Daily Injection ◽  
Multiple Daily Injection
Sign in / Sign up

Export Citation Format

Share Document